Tolerance

Tolerance is the phenomenon of needing more of a substance to produce the same effect, or of getting less of an effect from the same dose. It is one of the best-established findings in pharmacology and addiction science, appears among the diagnostic criteria for substance use disorders in the fifth edition of the Diagnostic and Statistical Manual, and has been demonstrated across opioids, alcohol, benzodiazepines and stimulants in animals and in humans. No named originator can be credited for the term. The extension of the concept to non-drug behaviours is much weaker and is best treated as analogy.
What it is
Tolerance is produced by neuroadaptation. The system that responded to the first dose adjusts to the repeated presence of it, so the same input meets a changed receiver. Two descriptions, escalation and diminishing return, are the same phenomenon seen from either end: escalation is tolerance observed in behaviour, and diminishing return is tolerance observed in experience.
The formal account the vault leans on is Richard Solomon and John Corbit's opponent-process theory of motivation, published in Psychological Review in 1974, in which a compensatory process opposing the initial effect grows with repetition. A second mechanism belongs beside it and is often left out. Shepard Siegel's work from 1975 onwards showed that tolerance is partly learned and tied to context, which is the standard explanation for why a familiar dose taken in an unfamiliar setting is more dangerous than the same dose in the usual one.
In effect
Anna Lembke's Dopamine Nation is where this concept reaches the library, and her clinical cases run the shape at a range of stakes, most sharply in the opioid patients she describes whose pain improved on tapering, which on her account is tolerance and opioid-induced hyperalgesia together. She also uses non-drug examples, reading and then more explicit reading, where the same material stops working and the time spent lengthens.
Two sourcing points are recorded with the concept. Lembke defines tolerance and credits nobody, which is unremarkable for a term this established. More usefully, the word itself is absent from several chapters where the mechanism is doing all the work, so a reader meets the phenomenon repeatedly and the name for it only intermittently, and an unnamed construct cannot be checked. The escalation arithmetic that circulates from that book, a set of dopamine percentages in laboratory animals and the comparison derived from them, is barred by the book's own reliability audit and is not reproduced here.
Where this publication lands: the drug case is robust, and the behavioural extension overlaps heavily with hedonic adaptation and should be labelled as analogy when it is used. Behavioural tolerance in gambling is recognised in the diagnostic manual; for most other behaviours the evidence is thin.
What it does not say
It does not say that any repeated pleasure produces clinical tolerance. The ordinary fading of a new pleasure is hedonic adaptation, and it needs no pharmacology to explain it.
It does not describe or recommend anything anyone should do about a substance, a dose or a schedule. Nothing here is clinical guidance, and anyone with a question about their own use needs a clinician rather than a concept page.
It does not explain addiction on its own. Tolerance is one feature among several, and the accounts that reach for it as a complete explanation are reaching beyond what it supports.
Sources
- Solomon, R. L., & Corbit, J. D. (1974). "An opponent-process theory of motivation." Psychological Review, 81(2), 119-145. The formal account the concept leans on.
- Siegel, S. Work from 1975 onwards on conditioned, context-dependent tolerance, the main qualification to a purely receptor-level account.
- Tolerance appears among the diagnostic criteria for substance use disorders in DSM-5 and has been demonstrated across opioids, alcohol, benzodiazepines and stimulants in animals and humans. No named originator can be credited for the term.
- Dopamine Nation, Anna Lembke. Defined in the text and credited to nobody. The word is absent from several chapters where the mechanism is doing the work. The rat dopamine percentages at p. 50 and the comparison derived from them are barred by the book hub and are not reproduced.
- The Molecule of More, for the onset-of-action argument, that how fast a drug arrives matters as much as how much of it there is. This book is never the authority for pharmacology; see The Uncited Mechanism.
- Evidence status robust for the pharmacological case, following the verification verdict of 2026-09-25, which supersedes the earlier unreviewed reading in the vault note. The behavioural extension is weaker and is treated as analogy.